Yukio Kawahara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yukio Kawahara has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Taisuke Nakahama
Department of RNA Biology and Neuroscience, Osaka University, Suita, Osaka, Japan
9 shared publications Taisuke Nakahama
Department of RNA Biology and Neuroscience, Graduate School of Medicine, Osaka University, Suita, Japan
7 shared publicationsToshiharu Shibuya
Department of RNA Biology and Neuroscience, The University of Osaka Graduate School of Medicine, Suita, Osaka, 565-0871, Japan
7 shared publicationsYuki Kato
Department of RNA Biology and Neuroscience, The University of Osaka Graduate School of Frontier Biosciences, Suita, Osaka 565-0871, Japan; The University of Osaka Graduate School of Medicine, Suita, Osaka 565-0871, Japan; Integrated Frontier Research for Medical Science Division and RNA Frontier Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), The University of Osaka, Suita, Osaka 565-0871, Japan
7 shared publicationsHiroyuki Todo
Department of RNA Biology and Neuroscience, The University of Osaka Graduate School of Medicine, Suita, Osaka, 565-0871, Japan
6 shared publicationsPedro Henrique Costa Cruz
Department of RNA Biology and Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan
6 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Neuron-specific deletion of ADAR1 induces brain malformation and early postnatal lethality
Adenosine deaminase acting on RNA 1 (ADAR1), which mediates adenosine-to-inosine RNA editing, is expressed as two isoforms, p110 and p150. Deletion of Adar1 p150 in mice results in embryonic lethality caused by aberrant activation of melanoma differentiation-associated protein 5 (MDA5)-mediated sensing of unedited endogenous transcripts, whereas Adar1 p110-specific deficient mice die postnatally through RNA editing-independent mechanisms. ADAR1 mutations cause Aicardi-Goutières syndrome (AGS), a congenital autoinflammatory disease accompanied by encephalopathy with a type I interferon (IFN) signature. However, the roles of ADAR1 in neurons remain elusive. Here, we show that neuron-specific deletion of Adar1 (both p110 and p150) in mice caused early postnatal lethality with elevated expression of type I IFN-stimulated genes (ISGs). Ventricular obstruction due to hypoplasia of the choroid plexus and ependymal cells, which was accompanied by gliosis, was observed. Of note, both selective restoration of ADAR1 p150 function and deletion of MDA5 largely normalized type I ISG expression and ameliorated ventricular obstruction but failed to rescue early postnatal lethality. Furthermore, selective restoration of RNA editing-independent function of ADAR1 p110 was also insufficient to rescue the early postnatal lethality, suggesting that both ADAR1 p110 and p150 in neurons are essential for postnatal survival.
- 3 July 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessNeuron-specific deletion of ADAR1 induces brain malformation and early postnatal lethality
Adenosine deaminase acting on RNA 1 (ADAR1), which mediates adenosine-to-inosine RNA editing, is expressed as two isoforms, p110 and p150. Deletion of Adar1 p150 in mice results in embryonic lethality caused by aberrant activation of melanoma differentiation-associated protein 5 (MDA5)-mediated sensing of unedited endogenous transcripts, whereas Adar1 p110-specific deficient mice die postnatally through RNA editing-independent mechanisms. ADAR1 mutations cause Aicardi-Goutières syndrome (AGS), a congenital autoinflammatory disease accompanied by encephalopathy with a type I interferon (IFN) signature. However, the roles of ADAR1 in neurons remain elusive. Here, we show that neuron-specific deletion of Adar1 (both p110 and p150) in mice caused early postnatal lethality with elevated expression of type I IFN-stimulated genes (ISGs). Ventricular obstruction due to hypoplasia of the choroid plexus and ependymal cells, which was accompanied by gliosis, was observed. Of note, both selective restoration of ADAR1 p150 function and deletion of MDA5 largely normalized type I ISG expression and ameliorated ventricular obstruction but failed to rescue early postnatal lethality. Furthermore, selective restoration of RNA editing-independent function of ADAR1 p110 was also insufficient to rescue the early postnatal lethality, suggesting that both ADAR1 p110 and p150 in neurons are essential for postnatal survival.
- Open Access
- 18 March 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (4) , 117113
Aberrant multicellular interferon signaling underlies Adar1 mutation–driven Aicardi-Goutières syndrome-like encephalopathy
- 18 March 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (4) , 117113
Open AccessAberrant multicellular interferon signaling underlies Adar1 mutation–driven Aicardi-Goutières syndrome-like encephalopathy
- Open Access
- 27 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
RNA modifications, alternative splicing and circular RNA landscape in the mouse brain: inosine and beyond
RNA modifications in the brain can be essential for regulating the transcriptome and brain function. Our study unveils the landscape of different RNA modifications associated with splicing within the mouse brain. Focusing on inosine, known for its role in alternative splicing modulation and enriched in introns, we investigated its influence using mice lacking ADAR2 alone or in combination with catalytically inactive ADAR1. While some alternative splicing-regulatory roles of inosine and ADAR enzymes are established, we observe that altering ADAR2 and ADAR1/ADAR2 is associated with changes in alternative splicing and coincides with shifts in levels of other RNA modification. Through the utilization of an innovative approach, we identified novel candidate circular RNA profiles in wild-type and mutant mice and detected potential inosine sites within circular RNAs. Collectively, our findings underscore a complex interplay among RNA modifications, alternative splicing, circular RNAs in the mouse brain.
- 27 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessRNA modifications, alternative splicing and circular RNA landscape in the mouse brain: inosine and beyond
RNA modifications in the brain can be essential for regulating the transcriptome and brain function. Our study unveils the landscape of different RNA modifications associated with splicing within the mouse brain. Focusing on inosine, known for its role in alternative splicing modulation and enriched in introns, we investigated its influence using mice lacking ADAR2 alone or in combination with catalytically inactive ADAR1. While some alternative splicing-regulatory roles of inosine and ADAR enzymes are established, we observe that altering ADAR2 and ADAR1/ADAR2 is associated with changes in alternative splicing and coincides with shifts in levels of other RNA modification. Through the utilization of an innovative approach, we identified novel candidate circular RNA profiles in wild-type and mutant mice and detected potential inosine sites within circular RNAs. Collectively, our findings underscore a complex interplay among RNA modifications, alternative splicing, circular RNAs in the mouse brain.
- Open Access
- 24 June 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (7) , 112688
A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth
- 24 June 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (7) , 112688
Open AccessA cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth
- Open Access
- 18 May 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (7) , 104840
RNA editing of AZIN1 coding sites is catalyzed by ADAR1 p150 after splicing
- 18 May 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (7) , 104840
Open AccessRNA editing of AZIN1 coding sites is catalyzed by ADAR1 p150 after splicing
- Open Access
RNA editing of AZIN1 coding sites is catalyzed by ADAR1 p150 after splicing
Adenosine-to-inosine RNA editing is catalyzed by nuclear ADAR1 p110 and ADAR2, and cytoplasmic ADAR1 p150 in mammals, all of which recognize double-stranded RNAs (dsRNAs) as targets. Although its frequency is quite rare, RNA editing occurs in coding regions, which alters protein functions by exchanging amino acid sequences, and is therefore physiologically significant. In general, such coding sites are edited by ADAR1 p110 and ADAR2 prior to splicing, given that the corresponding exon forms a dsRNA structure with an adjacent intron. We previously found that RNA editing at two coding sites of antizyme inhibitor 1 (AZIN1) is sustained in Adar1 p110/Aadr2 double knockout mice. However, the molecular mechanisms underlying RNA editing of AZIN1 remain unknown. Here, we showed that Azin1 editing levels were increased upon type I interferon treatment, which activated Adar1 p150 transcription, in mouse Raw264.7 cells. Azin1 RNA editing was observed in mature mRNA but not precursor mRNA. Furthermore, we revealed that the two coding sites were editable only by ADAR1 p150 in both mouse Raw264.7 and human HEK293T cells. This unique editing was achieved by forming a dsRNA structure with a downstream exon after splicing and the intervening intron suppressed RNA editing. Therefore, deletion of a nuclear export signal from ADAR1 p150, shifting its localization to the nucleus, decreased Azin1 editing levels. Finally, we demonstrated that Azin1 RNA editing was completely absent in Adar1 p150 knockout mice. Thus, these findings indicate that RNA editing of AZIN1 coding sites is exceptionally catalyzed by ADAR1 p150 after splicing.
Open AccessRNA editing of AZIN1 coding sites is catalyzed by ADAR1 p150 after splicing
Adenosine-to-inosine RNA editing is catalyzed by nuclear ADAR1 p110 and ADAR2, and cytoplasmic ADAR1 p150 in mammals, all of which recognize double-stranded RNAs (dsRNAs) as targets. Although its frequency is quite rare, RNA editing occurs in coding regions, which alters protein functions by exchanging amino acid sequences, and is therefore physiologically significant. In general, such coding sites are edited by ADAR1 p110 and ADAR2 prior to splicing, given that the corresponding exon forms a dsRNA structure with an adjacent intron. We previously found that RNA editing at two coding sites of antizyme inhibitor 1 (AZIN1) is sustained in Adar1 p110/Aadr2 double knockout mice. However, the molecular mechanisms underlying RNA editing of AZIN1 remain unknown. Here, we showed that Azin1 editing levels were increased upon type I interferon treatment, which activated Adar1 p150 transcription, in mouse Raw264.7 cells. Azin1 RNA editing was observed in mature mRNA but not precursor mRNA. Furthermore, we revealed that the two coding sites were editable only by ADAR1 p150 in both mouse Raw264.7 and human HEK293T cells. This unique editing was achieved by forming a dsRNA structure with a downstream exon after splicing and the intervening intron suppressed RNA editing. Therefore, deletion of a nuclear export signal from ADAR1 p150, shifting its localization to the nucleus, decreased Azin1 editing levels. Finally, we demonstrated that Azin1 RNA editing was completely absent in Adar1 p150 knockout mice. Thus, these findings indicate that RNA editing of AZIN1 coding sites is exceptionally catalyzed by ADAR1 p150 after splicing.
- 5 December 2022
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 35 (3) , 123-133
The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways
Adenosine deaminase acting on RNA 1 (ADAR1) is an RNA-editing enzyme that catalyzes adenosine-to-inosine conversions in double-stranded RNAs (dsRNAs). In mammals, ADAR1 is composed of two isoforms: a nuclear short p110 isoform and a cytoplasmic long p150 isoform. Whereas both isoforms contain right-handed dsRNA-binding and deaminase domains, ADAR1 p150 harbors a Zα domain that binds to left-handed dsRNAs, termed Z-RNAs. MDA5 sensing of endogenous dsRNAs as non-self leads to the induction of type I interferon (IFN)-stimulated genes, but recent studies revealed that ADAR1 p150-mediated RNA editing, but not ADAR1 p110, prevents this MDA5-mediated sensing. ADAR1 p150-specific RNA-editing sites are present and at least a Zα domain–Z-RNA interaction is required for this specificity. Mutations in the ADAR1 gene cause Aicardi–Goutières syndrome (AGS), an infant encephalopathy with type I IFN overproduction. Insertion of a point mutation in the Zα domain of the Adar1 gene induces AGS-like encephalopathy in mice, which is rescued by concurrent deletion of MDA5. This finding indicates that impaired ADAR1 p150-mediated RNA-editing is a mechanism underlying AGS caused by an ADAR1 mutation. ADAR1 p150 also prevents ZBP1 sensing of endogenous Z-RNA, which leads to programmed cell death, via the Zα domain and its RNA-editing activity. Furthermore, ADAR1 prevents PKR sensing of endogenous right-handed dsRNAs, which leads to translational shutdown and growth arrest. Thus, ADAR1 acts as a regulatory hub that blocks sensing of endogenous dsRNAs as non-self by multiple sensor proteins, both in RNA editing-dependent and -independent manners, and is a potential therapeutic target for diseases, especially cancer.
- 5 December 2022
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 35 (3) , 123-133
The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways
Adenosine deaminase acting on RNA 1 (ADAR1) is an RNA-editing enzyme that catalyzes adenosine-to-inosine conversions in double-stranded RNAs (dsRNAs). In mammals, ADAR1 is composed of two isoforms: a nuclear short p110 isoform and a cytoplasmic long p150 isoform. Whereas both isoforms contain right-handed dsRNA-binding and deaminase domains, ADAR1 p150 harbors a Zα domain that binds to left-handed dsRNAs, termed Z-RNAs. MDA5 sensing of endogenous dsRNAs as non-self leads to the induction of type I interferon (IFN)-stimulated genes, but recent studies revealed that ADAR1 p150-mediated RNA editing, but not ADAR1 p110, prevents this MDA5-mediated sensing. ADAR1 p150-specific RNA-editing sites are present and at least a Zα domain–Z-RNA interaction is required for this specificity. Mutations in the ADAR1 gene cause Aicardi–Goutières syndrome (AGS), an infant encephalopathy with type I IFN overproduction. Insertion of a point mutation in the Zα domain of the Adar1 gene induces AGS-like encephalopathy in mice, which is rescued by concurrent deletion of MDA5. This finding indicates that impaired ADAR1 p150-mediated RNA-editing is a mechanism underlying AGS caused by an ADAR1 mutation. ADAR1 p150 also prevents ZBP1 sensing of endogenous Z-RNA, which leads to programmed cell death, via the Zα domain and its RNA-editing activity. Furthermore, ADAR1 prevents PKR sensing of endogenous right-handed dsRNAs, which leads to translational shutdown and growth arrest. Thus, ADAR1 acts as a regulatory hub that blocks sensing of endogenous dsRNAs as non-self by multiple sensor proteins, both in RNA editing-dependent and -independent manners, and is a potential therapeutic target for diseases, especially cancer.
- Open Access
- 28 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
The N6-methyladenosine methyltransferase METTL16 enables erythropoiesis through safeguarding genome integrity
During erythroid differentiation, the maintenance of genome integrity is key for the success of multiple rounds of cell division. However, molecular mechanisms coordinating the expression of DNA repair machinery in erythroid progenitors are poorly understood. Here, we discover that an RNA N6-methyladenosine (m6A) methyltransferase, METTL16, plays an essential role in proper erythropoiesis by safeguarding genome integrity via the control of DNA-repair-related genes. METTL16-deficient erythroblasts exhibit defective differentiation capacity, DNA damage and activation of the apoptotic program. Mechanistically, METTL16 controls m6A deposition at the structured motifs in DNA-repair-related transcripts including Brca2 and Fancm mRNAs, thereby upregulating their expression. Furthermore, a pairwise CRISPRi screen revealed that the MTR4-nuclear RNA exosome complex is involved in the regulation of METTL16 substrate mRNAs in erythroblasts. Collectively, our study uncovers that METTL16 and the MTR4-nuclear RNA exosome act as essential regulatory machinery to maintain genome integrity and erythropoiesis.
- 28 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Open AccessThe N6-methyladenosine methyltransferase METTL16 enables erythropoiesis through safeguarding genome integrity
During erythroid differentiation, the maintenance of genome integrity is key for the success of multiple rounds of cell division. However, molecular mechanisms coordinating the expression of DNA repair machinery in erythroid progenitors are poorly understood. Here, we discover that an RNA N6-methyladenosine (m6A) methyltransferase, METTL16, plays an essential role in proper erythropoiesis by safeguarding genome integrity via the control of DNA-repair-related genes. METTL16-deficient erythroblasts exhibit defective differentiation capacity, DNA damage and activation of the apoptotic program. Mechanistically, METTL16 controls m6A deposition at the structured motifs in DNA-repair-related transcripts including Brca2 and Fancm mRNAs, thereby upregulating their expression. Furthermore, a pairwise CRISPRi screen revealed that the MTR4-nuclear RNA exosome complex is involved in the regulation of METTL16 substrate mRNAs in erythroblasts. Collectively, our study uncovers that METTL16 and the MTR4-nuclear RNA exosome act as essential regulatory machinery to maintain genome integrity and erythropoiesis.
- Open Access
- 14 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-11
Alignment of single-cell trajectory trees with CAPITAL
Global alignment of complex pseudotime trajectories between different single-cell RNA-seq datasets is challenging, as existing tools mainly focus on linear alignment of single-cell trajectories. Here we present CAPITAL (comparative analysis of pseudotime trajectory inference with tree alignment), a method for comparing single-cell trajectories with tree alignment whereby branching trajectories can be automatically compared. Computational tests on synthetic datasets and authentic bone marrow cells datasets indicate that CAPITAL has achieved accurate and robust alignments of trajectory trees, revealing various gene expression dynamics including gene–gene correlation conservation between different species.
- 14 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-11
Open AccessAlignment of single-cell trajectory trees with CAPITAL
Global alignment of complex pseudotime trajectories between different single-cell RNA-seq datasets is challenging, as existing tools mainly focus on linear alignment of single-cell trajectories. Here we present CAPITAL (comparative analysis of pseudotime trajectory inference with tree alignment), a method for comparing single-cell trajectories with tree alignment whereby branching trajectories can be automatically compared. Computational tests on synthetic datasets and authentic bone marrow cells datasets indicate that CAPITAL has achieved accurate and robust alignments of trajectory trees, revealing various gene expression dynamics including gene–gene correlation conservation between different species.
- 15 December 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (12) , 3016-3027
An Aicardi-Goutières Syndrome–Causative Point Mutation in Adar1 Gene Invokes Multiorgan Inflammation and Late-Onset Encephalopathy in Mice
Aicardi–Goutières syndrome (AGS) is a congenital inflammatory disorder accompanied by overactivated type I IFN signaling and encephalopathy with leukodystrophy and intracranial calcification. To date, none of the mouse models carrying an AGS-causative mutation has mimicked such brain pathology. Here, we established a mutant mouse model carrying a K948N point mutation, corresponding to an AGS-causative K999N mutation, located in a deaminase domain of the Adar1 gene that encodes an RNA editing enzyme. Adar1K948N/K948N mice displayed postnatal growth retardation. Hyperplasia of splenic white pulps with germinal centers and hepatic focal inflammation were observed from 2 mo of age. Inflammation developed in the lungs and heart with lymphocyte infiltration in an age-dependent manner. Furthermore, white matter abnormalities with astrocytosis and microgliosis were detected at 1 y of age. The increased expression of IFN-stimulated genes was detected in multiple organs, including the brain, from birth. In addition, single-nucleus RNA sequencing revealed that this elevated expression of IFN-stimulated genes was commonly observed in all neuronal subtypes, including neurons, oligodendrocytes, and astrocytes. We further showed that a K948N point mutation reduced the RNA editing activity of ADAR1 in vivo. The pathological abnormalities found in Adar1K948N/K948N mice were ameliorated by either the concurrent deletion of MDA5, a cytosolic sensor of unedited transcripts, or the sole expression of active ADAR1 p150, an isoform of ADAR1. Collectively, such data suggest that although the degree is mild, Adar1K948N/K948N mice mimic multiple AGS phenotypes, including encephalopathy, which is caused by reduced RNA editing activity of the ADAR1 p150 isoform. Key Points Multiorgan inflammation with IFN signature is observed in Adar1K948N/K948N mice. White matter abnormalities and gliosis are detected in aged Adar1K948N/K948N mice. A K948N point mutation reduces ADAR1 p150–mediated RNA editing, activating MDA5.
- 15 December 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (12) , 3016-3027
An Aicardi-Goutières Syndrome–Causative Point Mutation in Adar1 Gene Invokes Multiorgan Inflammation and Late-Onset Encephalopathy in Mice
Aicardi–Goutières syndrome (AGS) is a congenital inflammatory disorder accompanied by overactivated type I IFN signaling and encephalopathy with leukodystrophy and intracranial calcification. To date, none of the mouse models carrying an AGS-causative mutation has mimicked such brain pathology. Here, we established a mutant mouse model carrying a K948N point mutation, corresponding to an AGS-causative K999N mutation, located in a deaminase domain of the Adar1 gene that encodes an RNA editing enzyme. Adar1K948N/K948N mice displayed postnatal growth retardation. Hyperplasia of splenic white pulps with germinal centers and hepatic focal inflammation were observed from 2 mo of age. Inflammation developed in the lungs and heart with lymphocyte infiltration in an age-dependent manner. Furthermore, white matter abnormalities with astrocytosis and microgliosis were detected at 1 y of age. The increased expression of IFN-stimulated genes was detected in multiple organs, including the brain, from birth. In addition, single-nucleus RNA sequencing revealed that this elevated expression of IFN-stimulated genes was commonly observed in all neuronal subtypes, including neurons, oligodendrocytes, and astrocytes. We further showed that a K948N point mutation reduced the RNA editing activity of ADAR1 in vivo. The pathological abnormalities found in Adar1K948N/K948N mice were ameliorated by either the concurrent deletion of MDA5, a cytosolic sensor of unedited transcripts, or the sole expression of active ADAR1 p150, an isoform of ADAR1. Collectively, such data suggest that although the degree is mild, Adar1K948N/K948N mice mimic multiple AGS phenotypes, including encephalopathy, which is caused by reduced RNA editing activity of the ADAR1 p150 isoform. Key Points Multiorgan inflammation with IFN signature is observed in Adar1K948N/K948N mice. White matter abnormalities and gliosis are detected in aged Adar1K948N/K948N mice. A K948N point mutation reduces ADAR1 p150–mediated RNA editing, activating MDA5.